For example, in colorectal cancer, the addition of JQ1 to mTOR inhibitors was thought to synergize through suppressing oncogenic kinases (33), while in rhabdomyosarcoma, combined BETi + mTORC1/2i–induced necroptosis-mediated cell death. Here, MTOR is linked to rhabdomyosarcoma.